Posted on 10/26/17
Celgene's GED-0301 Failure Offers A Peek At The Value Of Synergy's Dolcanatide
Celgene Corporation (NASDAQ:CELG), a global pharmaceutical company based in the mid-Atlantic, recently announced that the company has discontinuedtheir Phase 3 trial for their drug, GED-0301. GED-0301 . . .
Posted on 9/6/17
Synergy Pharma: It Takes Money To Make Money
Synergy Pharmaceuticals (NASDAQ:SGYP), a gastrointestinal focused company out of New York, has probably announced their most significant news yet since the launch of their prized drug, . . .
Posted on 6/2/17
Xenetic Biosciences Hits A Bit Of A Snag, But Still Highly Promising
Xenetic Biosciences (NASDAQ:XBIO), a biopharmaceutical company which focuses on the research and development of biologic drugs and novel oncology therapeutics, recently received an update from its . . .
Boston
